Humanized PD-L1 Rodent Models for Accurate Cancer Drug Screening
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer drug development methods, particularly those involving antibody drugs targeting immunological checkpoints, face challenges due to the inability of traditional in vitro and in vivo screening approaches to accurately replicate human tumor microenvironments, leading to high failure rates and discrepancies between animal and clinical trial results.
Innovation Solution
The development of genetically modified rodents expressing human or chimeric PD-L1 proteins, allowing for the creation of humanized animal models that can accurately mimic human PD-L1 target sites, facilitating drug screening and evaluation, and enabling the study of PD-L1 function and cancer therapy efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If traditional in vitro screening approaches are used, then drug development can proceed with simpler methods, but the results cannot accurately reflect human tumor microenvironment and lead to high failure rates
Solution Approach 1:
The patent changes the biological parameters of the animal model by introducing humanized immune system components (human T cells, human PD-L1 expression) into immunodeficient mice. This parameter change enables the model to better replicate human tumor microenvironment while maintaining the ease of in vivo experimentation, thus resolving the contradiction between screening simplicity and result accuracy.
Solution Approach 2:
The patent uses humanized animal models as an intermediary system between in vitro screening and clinical trials. These models serve as a bridge that incorporates human biological elements (human immune cells, human PD-L1 targets) within an animal physiology framework, allowing drug screening to occur in a living system that more accurately predicts human response while avoiding the complexity and ethical constraints of human clinical trials.
2Adaptability or versatility
If conventional experimental animals are used for in vivo pharmacological tests, then animal experimentation can be conducted with existing models, but the test results cannot reflect real human disease state and targeting site interactions
Solution Approach 1:
The patent applies local quality by selectively humanizing specific components of the animal model rather than attempting to create a fully human system. Specifically, the mice are engineered to express human PD-L1 on tumor cells and/or human immune cells while maintaining mouse physiology for other functions. This localized humanization provides accurate representation of the PD-L1 target site and immune interactions without requiring complete humanization of the organism.
Solution Approach 2:
The patent creates a composite biological system combining mouse physiology with human cellular and molecular components. The humanized animal model consists of mouse tissue structures populated with human immune cells and human PD-L1 expression, forming a hybrid system that leverages the advantages of both species - the controllable physiology of mice combined with the human-specific target molecules and immune responses.
3Reliability
If humanized animal models are developed to accurately mimic human PD-L1 target sites, then drug screening accuracy improves, but model complexity and development costs increase
Solution Approach 1:
The patent implements partial humanization by introducing only the specific human elements necessary for PD-L1 target validation - namely human PD-L1 expression in tumor cells and/or human immune cell components - rather than attempting full humanization of the animal model. This partial approach provides sufficient accuracy for antibody screening against human PD-L1 while avoiding the excessive complexity and costs associated with complete humanization.
Data Source
Figure 1
Figure 2
Figure 3
AI summary
Disclosed is a genetically modified expressing human or chemeric (e. g., humanized) programmed death-ligand 1 (PD-L1, PDL1, or B7-H1), and methods of use thereof.